Krispy Kreme Inc
For the period ended Sep 29, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 29, 2024 · Filed Nov 8, 2024
DNUT$3.85-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Three Quarters Ended | ||
|---|---|---|
| September 29,2024 (39 weeks) | October 1,2023 (39 weeks) | |
| CASH FLOWS PROVIDED BY OPERATING ACTIVITIES: | ||
| Net income/(loss) | $25,978 | $(38,530) |
| Adjustments to reconcile net income/(loss) to net cash provided by operating activities: | ||
| Depreciation and amortization expense | 99,562 | 89,142 |
| Deferred and other income taxes | (22) | 12,634 |
| Loss on extinguishment of debt | — | 472 |
| Impairment and lease termination charges | 368 | 7,711 |
| Loss/(gain) on disposal of property and equipment | 470 | (168) |
| Gain on divestiture of Insomnia Cookies | (87,128) | — |
| Gain on remeasurement of equity method investment | (5,579) | — |
| Gain on sale-leaseback | — | (9,646) |
| Share-based compensation | 24,603 | 17,821 |
| Change in accounts and notes receivable allowances | 433 | 504 |
| Inventory write-off | 1,731 | 10,522 |
| Settlement of interest rate swap derivatives | — | 7,657 |
| Amortization related to settlement of interest rate swap derivatives | (5,910) | (7,334) |
| Other | 263 | 566 |
| Change in operating assets and liabilities, excluding business acquisitions and divestitures, and foreign currency translation adjustments | (35,982) | (47,319) |
| Net cash provided by operating activities | 18,787 | 44,032 |
| CASH FLOWS PROVIDED BY/(USED FOR) INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (86,877) | (88,605) |
| Proceeds from sale-leaseback | — | 10,025 |
| Acquisition of shops and franchise rights from franchisees, net of cash acquired | (26,612) | — |
| Purchase of equity method investment | (3,506) | — |
| Net proceeds from divestiture of Insomnia Cookies | 117,646 | — |
| Principal payment received from loan to Insomnia Cookies | 45,000 | — |
| Disbursement for loan receivable | (1,086) | — |
| Other investing activities | 180 | 222 |
| Net cash provided by/(used for) investing activities | 44,745 | (78,358) |
| CASH FLOWS (USED FOR)/PROVIDED BY FINANCING ACTIVITIES: | ||
| Proceeds from the issuance of debt | 490,000 | 1,044,698 |
| Repayment of long-term debt and lease obligations | (545,692) | (965,250) |
| Payment of financing costs | — | (5,000) |
| Proceeds from structured payables | 298,551 | 145,099 |
| Payments on structured payables | (264,346) | (159,571) |
| Payment of contingent consideration related to a business combination | — | (925) |
| Capital contribution by shareholders, net of loans issued | 919 | 631 |
| Proceeds from sale of noncontrolling interest in subsidiary | 364 | — |
| Distribution to shareholders | (17,743) | (17,657) |
| Payments for repurchase and retirement of common stock | (4,366) | (1,609) |
| Distribution to noncontrolling interest | (35,035) | (12,883) |
| Net cash (used for)/provided by financing activities | (77,348) | 27,533 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,086 | (2,796) |
| Net decrease in cash, cash equivalents and restricted cash | (12,730) | (9,589) |
| Cash, cash equivalents and restricted cash at beginning of period | 38,614 | 35,730 |
| Cash, cash equivalents and restricted cash at end of period | $25,884 | $26,141 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Increase in accrual for property and equipment | $12,362 | $30,616 |
| Accrual for distribution to shareholders | (5,943) | (5,901) |
| Reconciliation of cash, cash equivalents and restricted cash at end of period: | ||
| Cash and cash equivalents | $25,410 | $25,711 |
| Restricted cash | 474 | 430 |
| Total cash, cash equivalents and restricted cash | $25,884 | $26,141 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.